This study will enroll patients with KRASG12C mutant NSCLC not previously treated with KRASG12C inhibitors. Patients in this study will receive ladarixin and sotorasib. The primary objective of the Phase I portion is to define a recommended phase II dose (RP2D) of ladarixin when combined with sotorasib.
This is a phase I, open-label, study of twice-daily oral ladarixin in patients with advanced KRAS G12C mutant non-small cell lung cancer (NSCLC) with sotorasib.